Synthesis, antiplatelet aggregation activity, and molecular modeling study of novel substituted-piperazine analogues

Medicinal Chemistry Research

Volumn 20, Issue 7, 2011, Pages 898-911

  Youssef, Khairia M ^a   Al Omar, Mohamed A ^b   El Subbagh, Hussein I ^b   Abou zeid, Laila A ^c   Abdel Gader, Abdel Galil M ^d   Haress, Abdel Galil M ^b   Al Tuwaijri, Ali S ^d  

^a FUTURE UNIVERSITY IN EGYPT   (Egypt)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c University of Mansoura   (Egypt)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antiplatelet aggregation; Molecular modeling studies; Piperazine analogues; Synthesis

Indexed keywords

1,4 BIS [3 (N4 ARYL N1 PIPERAZINO CARBONYL) PIPERIDIN 1 YL METHYL] BENZENE DIBROMIDE; 1,4 BIS [3 (N4 ARYL N1 PIPERAZINO CARBONYL) PYRIDINIUM 1 YL METHYL] BENZENE DIBROMIDE; 1,4 BIS [3 [N4 (2 CHLOROPHENY N1 (PIPERAZINOCARBONYL)] PIPERIDIN 1 YL METHYL] BENZENE DIBROMIDE; N1 (1 ARALKYL 3 PIPERIDINO CARBONYL) N4 ARYL PIPERAZINE HYDROHALIDE; N1 (1 ARALKYL PYRIDINIUM 3 YL CARBONYL) N4 ARYL PIPERAZINE HALIDE; N1 (1 AROYL 4 PIPERIDINO CARBONYL) N4 ARYL PIPERAZINE HYDROHALIDE; N1 (1 AROYL PYRIDINIUM 3 YL CARBONYL) N4 ARYL PIPERAZINE HALIDE; N1 (3 PYRIDINO CARBONYL) N4 ARYL PIPERAZINE HYDROCHLORIDE; N1 [1 (4 BROMOBENZYL) 3 PIPERIDINOCARBONYL N4 (2 CHLOROPHENYL) PIPERAZINE HYDROBROMIDE; N1,N4 BIS (1 ARALKYL PIPERIDINO 3 YL CARBONYL) PIPERAZINE DIHYDRO HALIDE; N1,N4 BIS (1 ARALKYL PYRIDINIUM 3 YL CARBONYL) PIPERAZINE DIHALIDE; N1,N4 BIS (1 AROYL PIPERIDINO 3 YL CARBONYL) PIPERAZINE DIHYDRO HALIDE; N1,N4 BIS (1 AROYL PYRIDINIUM 3 YL CARBONYL) PIPERAZINE DIHALIDE; N1,N4 BIS [3 PYRIDINO CARBONYL] PIPERAZINE DIHYDROCHLORIDE; NIPECOTIC ACID; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; DRUG ACTIVITY; LIPOPHILICITY; MOLECULAR MODEL; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; THROMBOCYTE AGGREGATION INHIBITION;

EID: 80054722466     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9411-5     Document Type: Article

References (32)

1. Antithrombotic Trialists' Collaboration (2002) Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324:71-86
2. Banner DW, Hadvary P (1991) Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active sitedirected inhibitors. J Biol Chem v266:20085-20093 (Pubitemid 21908430)
3. Berger PB (1999) The thienopyridines in coronary artery disease. Curr Cardiol Rep 1:192-198
4. Binisti C, Assogba L, Touboul E, Mounier C, Huet J, Ombetta J-E, Dong CZ, Redeuilh C, Heymans F, Godfroid J-J (2001) Structure-activity relationships in platelet-activating factor (PAF). 11-From PAF-antagonism to phospholipase A2 inhibition: Syntheses and structure-activity relationships in 1-arylsulfamido-2-alkylpiperazines. Eur J Med Chem 36:809-828 (Pubitemid 34001626)
5. Budin N, Majeux N, Caflisch A (2001) Fragment-based flexible ligand docking by evolutionary optimization. Biol Chem 382:1365-1372 (Pubitemid 32976495)
6. Chatelain P, Massingham R (1997) Cardiac ischaemia: Possibilities for future drug therapy. Eur J Med Chem 32:687-707 (Pubitemid 27380208)
7. Cody WL, Cai C, Doherty AM, Edmunds JJ, He JX, Narasimhan LS, Plummer JS, Rapundalo ST, Rubin JR, Van Huis CA, St-Denis Y, Winocour PD, Siddiqui MA (1999) The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: Part 1. Bioorg Med Chem Lett 9:2497-2502 (Pubitemid 29435526)
8. De Candia M, Fossa P, Cellamare S, Mosti L, Carotti A, Altomare C (2005) Insights into structure-activity relationships from lipophilicity profiles of pyridine-2(1H)-one analogs of the cardiotonic agent milrinone. Eur J Pharm Sci 26:78-86 (Pubitemid 41097264)
9. De Marco A, de Candia M, Carroti A, Cellamare S, De Candia E, Altomare C (2004) Lipophilicity-related inhibition of blood platelet aggregation by nipecotic acid anilides. Eur J Pharm Sci 22:153-164 (Pubitemid 38668680)
10. Dillingham EO, Lasslo A, Carter-Burks G, Bond SE, Gollamudi R (1989) Relationships between chemical structure and inhibition of ADP-stimulated human thrombocyte release of serotonin and platelet factor 4. Biochim Biophys Acta 990:128-132 (Pubitemid 19055404)
11. Dogné J-M, de Leval X, Benoit P, Delarge J, Masereel B, David J-L (2001) Recent advances in antiplatelet agents. Curr Med Chem 9:577-589 (Pubitemid 34436435)
12. Feng Z, Gollamudi R, Dillingham EO, Bond SE, Lyman BA, Purcell WP, Hill RJ, Korfmacher WA (1992) Molecular determinants of the platelet aggregation inhibitory activity of carbamoylpiperidines. J Med Chem 35:2952-2958
13. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326:242-250
14. Gachet C (2001) ADP receptors of platelets and their inhibition. Thromb Haemost 86:222-232 (Pubitemid 32663953)
15. Gader AMA, Bahakim HM, Jabbar FA, Lambourne AL, Gaafar TH, Edrees YB (1988) Dose-response aggregometry in maternal/ neonatal platelets. Thromb Haemostat 60:314-318
16. Heath JA, Mehrotra MM, Chi S, Yu J-C, Hutchaleelaha A, Hollenbach SJ, Giese NA, Scarborough RM, Pandey A (2004) Corrigendum to ''Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor. Bioorg Med Chem Lett 14:6133-6142
17. Hyperchem (1999) Molecular Modeling System, Hypercube, Inc., Release 6, Florida, USA
18. Kunapuli SP (1998) Multiple P2 receptor subtypes on platelets: A new interpretation of their function. Trends Pharmacol Sci 19: 391-394 (Pubitemid 28515670)
19. Leoncini G, Signorello MG, Roma G, Di Braccio M (1997) Effect of 2(1-piperazinyl)-4H-pyrido[1, 2-a]pyrimidin-4-one (AP155) on human platelets in vitro. Biochem Pharmacol 53:1667-1672 (Pubitemid 27356096)
20. Leoncini G, Signorello MG, Bruzzese D, Di Braccio M, Grossi GC, Roma G (2004) Mechanisms involved in the antiplatelet activity of 8-methyl-4-(1- piperazinyl)-7-(3-pyridinylmethoxy)-2H-1-benzopyran-2-one (RC414). Biochem Pharmacol 67:911-918 (Pubitemid 38201636)
21. Majerus W, Tollesfsen DM (2001) Anticoagulant, thrombolytic, and antiplatelet drugs. In: Goodman LS, Gilman AG, Limbird LE (eds) The Goodman Gilman's pharmacological basis of therapeutics. McGraw-Hill, New York, pp 1519-1537
22. McKee SA, Sane DC, Deliargyris EN (2002) Aspirin resistance in cardiovascular disease: A review of prevalence, mechanisms, and clinical significance. Thromb Haemost 88:711-715 (Pubitemid 35345324)
23. Mills DC (1996) ADP receptors on platelets. Thromb Haemost 76:835-856 (Pubitemid 27013617)
24. Papadopoulou C, Geronikaki A, Hadjipavlou-Litina D (2005) Synthesis and biological evaluation of new thiazolyl/benzothiazolylamides, derivatives of 4-phenylpiperazine. Farmaco 60:969-973 (Pubitemid 41586275)
25. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G (2001) Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 119:39S-63S (Pubitemid 32154194)
26. Sallem W, Serradji N, Dereuddre-Bosquet N, Dive G, Clayette P, Heymans F (2006) Structure-activity relationships in plateletactivating factor. Part 14: Synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity. Bioorg Med Chem Lett 14:7999-8013. (Pubitemid 44596257)
27. Slotboom AJ, Verheij HM, De Haas GH (1982) Specific transformations at the N-terminal region of phospholipase A2. In: Ansell GB (ed) Phospholipids. Elsevier, Amsterdam, pp 359-434
28. Storey F (2001) The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets 12:197-209
29. Tucker TJ, Lumma WC, Mulichak AM, Naylor-Olsen AM, Lewis SD, Lucas R, Freidinger RM, Kuo LC (1997) Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active Site. J Med Chem 40:830-832 (Pubitemid 27131611)
30. Van De Graaff E, Steinhubl SR (2000) Antiplatelet medications and their indications in preventing and treating coronary thrombosis. Ann Med 32:561-571
31. Weksler BB (2000) Antiplatelet agents in stroke prevention. Combination therapy: Present and future. Cerebrovasc Dis 10:41-48
32. Youssef KM, Al-Shafie FS (1998) ADP-and arachidonic acid (AA)-induced platelet aggregation inhibitory activity of carbamoylpyridines and carbamoylpiperidines. Al-Azhar Bull Sci 9:569-582